Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Israelis lack sleep and experience high anxiety amid the wars with Hamas and Iran as the two Middle East nations exchange ...

Shares of weight-loss drugmakers Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) spiked after the American College of Cardiology ...